DEBRA BARNES: Open Payments
NPI 1427788660 · NEWPORT NEWS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,843 in 132 payments from 16 companies in 2025. Trend: 2023 $948 · 2024 $2,182 · 2025 $2,843
Food & beverage: $2,843
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $769 |
| Janssen Biotech, Inc. | 24 | $489 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $431 |
| Ardelyx, Inc. | 8 | $191 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $187 |
| Lilly USA, LLC | 7 | $144 |
| Ipsen Biopharmaceuticals, Inc | 5 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $114 |
| PFIZER INC. | 5 | $113 |
| Gilead Sciences, Inc. | 3 | $69 |
Products named: TREMFYA, RINVOQ, ENTYVIO, IBSRELA, XIFAXAN, LINZESS, SKYRIZI, OMVOH.
Industry payments across VA — which companies pay providers there.
